Posted by Michael Wonder on 12 Jan 2021
Decision to widen access to valganciclovir for transplant patients
12 January 2021 - PHARMAC is pleased to announce a decision to widen access to valganciclovir for use after lung transplant and for patients who require further cytomegalovirus prophylaxis following pulse methylprednisolone treatment following transplant from 1 February 2021.
No changes have been made as a result of consultation feedback.
